← Insiders

CAH

Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.

Research, not advice.

À propos

Cardinal Health, Inc.

Nom
Cardinal Health, Inc.
Secteur
Healthcare
Industrie
Medical - Distribution
Bourse
NYSE
Capitalisation
$57.8B
Employés
61,344
PDG
Jason Hollar
Site web
https://www.cardinalhealth.com
Marché
CORHSICMCKSHPMYSHTDYSIG.AX

Cardinal Health, Inc. operates as a global, integrated provider of healthcare services and products, with its reach spanning the United States, Canada, Europe, Asia, and other international markets. The company delivers bespoke support to a diverse clientele, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical labs, physician practices, and individuals receiving care at home. It is structured into two core divisions: Pharmaceutical and Medical. The Pharmaceutical division oversees the distribution of a wide array of products, encompassing branded, generic, and specialty pharmaceuticals, along with over-the-counter health and consumer goods. This segment additionally offers specialized services to pharmaceutical manufacturers and healthcare providers, particularly for specialty pharmaceutical products. Its operations extend to managing nuclear pharmacies and facilities that produce radiopharmaceuticals. It also performs repackaging of generic drugs and OTC items. Further offerings include medication therapy management and patient outcomes services for hospitals, other healthcare providers, and payers, in addition to providing pharmacy management solutions to hospitals. The Medical division focuses on producing, sourcing, and supplying Cardinal Health-branded medical, surgical, and laboratory products and devices. This extensive product range encompasses items such as examination and surgical gloves, needles, syringes, sharps disposal units, compression products, incontinence aids, nutritional delivery systems, wound care supplies, single-use drapes, gowns, and apparel, fluid suction and collection devices, urological products, operating room essentials, and electrodes. Beyond its proprietary brands, this segment also distributes various national brand medical, surgical, and laboratory products. It offers comprehensive supply chain management for hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare organizations, and manufactures and sells both sterile and non-sterile procedure kits. Established in 1979, the company maintains its headquarters in Dublin, Ohio.

Price (1 year)

Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.

Decouvert par les declarations du Congres

Insiders
—
Total bought
—

Avg buy (VWAP, 90d window) —

Total sold
$13,895,718

Avg sell (VWAP, 90d window) $237.34 vs last close —

Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.

Last activity
—
Last synced
2026-10-06 10:56:08 Synced via automated research pipeline

Sign in to request a sync of this company's price history and timing levels.

Insider holdings as a share of total assets aren't available for this company.

Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.

Recent Form 4

Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.

Date Person Side Shares Price Value Form 4
2026-08-19 Hollar Jason M. Sell · S 6,244 $237.88 $1,485,323 Form 4
2026-08-19 Scherer Mary C. Sell · S 2,202 $237.39 $522,733 Form 4
2026-08-18 Alt Aaron E Sell · S 12,972 $237.26 $3,077,737 Form 4
2026-08-18 Greene Michelle D. Sell · S 686 $237.25 $162,754 Form 4
2026-08-18 Hollar Jason M. Sell · S 12,470 $237.25 $2,958,508 Form 4
2026-08-18 Mason Stephen M Sell · S 12,829 $237.26 $3,043,809 Form 4
2026-08-18 Mayer Jessica L Sell · S 10,864 $237.31 $2,578,136 Form 4
2026-08-18 WEITZMAN DEBORAH Sell · S 281 $237.44 $66,721 Form 4

Congressional trades

STOCK Act disclosures (90-day window)

Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.

No STOCK Act disclosures for this company in this window.

Recent trades

DateRepresentativeTypeAmount
2025-10-24Marjorie Taylor GreenePurchase$1,001 - $15,000
2025-09-05Ro KhannaSale$1,001 - $15,000
2025-05-14Marjorie Taylor GreenePurchase$1,001 - $15,000
2025-05-05Marjorie Taylor GreenePurchase$1,001 - $15,000
2025-04-08Robert P. BresnahanPurchase$1,001 - $15,000
2025-03-17Marjorie Taylor GreenePurchase$1,001 - $15,000
2025-01-21Marjorie Taylor GreenePurchase$1,001 - $15,000
2024-09-20Marjorie Taylor GreenePurchase$1,001 - $15,000
2024-09-04John JamesSale (Full)$1,001 - $15,000
2024-06-03John JamesPurchase$1,001 - $15,000
2024-05-02John JamesPurchase$1,001 - $15,000
2024-02-13Ro KhannaSale$1,001 - $15,000
2024-01-12Jonathan JacksonPurchase$50,001 - $100,000
2024-01-10Ro KhannaPurchase$1,001 - $15,000
2023-09-06Ro KhannaSale$1,001 - $15,000
2023-06-29Ro KhannaPurchase$1,001 - $15,000
2023-02-10Ro KhannaSale$1,001 - $15,000
2023-01-11Ro KhannaSale$1,001 - $15,000
2022-12-06Ro KhannaPurchase$1,001 - $15,000
2022-08-03Kathy E. ManningSale (Full)$1,001 - $15,000
2022-07-20Kathy E. ManningPurchase$1,001 - $15,000
2020-03-18Gilbert Ray CisnerosPurchase$1,001 - $15,000
2019-06-20Dean PhillipsSale (Full)$1,001 - $15,000
2019-02-04Dean PhillipsPurchase$1,001 - $15,000
2017-05-08Gary James PalmerSale (Full)$1,001 - $15,000
2017-04-10Gary James PalmerPurchase$1,001 - $15,000

Signal

Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.

CAH presents a moderate opportunity driven by a meaningful congressional trade signal (confidence: 0.72) and a concrete commercial catalyst — the binding LOI extending CVS Health distribution agreements — which aligns…

The first sentence of the analysis written for CAH on 2026-10-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.

Neutral signal Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.

Factor checklist — research, not advice

A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.

  • Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
  • Congress Supports a bullish reading. 6 purchase disclosures year to date
  • Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
  • Timing Unavailable or mixed. No stored price series
  • Financial indicators Pulls against a bullish reading. Current ratio 0.88 · operating margin 1.0%

Market snapshot

Financial ratios

MetricTrend2026-06-302025-06-302024-06-302023-06-302022-06-30
Gross Profit Margin3.8%3.7%3.3%3.4%3.6%
Ebit Margin1.0%1.0%0.6%0.4%-0.4%
Ebitda Margin1.4%1.4%0.9%0.7%0.0%
Operating Profit Margin1.0%1.0%0.5%0.4%-0.3%
Pretax Profit Margin0.9%0.9%0.5%0.3%-0.4%
Continuous Operations Profit Margin0.7%0.7%0.4%0.2%-0.5%
Net Profit Margin0.7%0.7%0.4%0.2%-0.5%
Bottom Line Profit Margin0.7%0.7%0.4%0.2%-0.5%
Current Ratio0.8830.9350.9791.0001.078
Quick Ratio0.4890.5020.5590.5220.566
Solvency Ratio0.0440.0420.0320.022-0.006
Cash Ratio0.1110.1000.1440.1210.154
Price To Earnings Ratio32.67725.92628.09275.056-15.650
Price To Earnings Growth Ratio2.6800.3010.159-0.5450.060
Forward Price To Earnings Growth Ratio2.6800.3010.159-0.5450.060
Price To Earnings Diluted Ratio32.85826.04728.33675.056-15.650
Price To Earnings Diluted Growth Ratio2.7170.3000.163-0.5450.060
Price To Book Ratio-19.446-14.559-7.454-8.344-20.569
Price To Sales Ratio0.2210.1820.1060.1200.080
Price To Free Cash Flow Ratio12.39021.8857.36710.4465.332
Price To Operating Cash Flow Ratio10.83616.8916.3678.6794.671
Debt To Assets Ratio0.1740.1760.1240.1190.132
Debt To Equity Ratio-3.451-3.360-1.746-1.750-8.188
Debt To Capital Ratio1.4081.4242.3412.3341.139
Long Term Debt To Capital Ratio1.7241.5523.3454.3161.178
Financial Leverage Ratio-19.875-19.102-14.043-14.655-61.887
Working Capital Turnover Ratio-66.254-135.718-597.700172.10762.429
Operating Cash Flow Ratio0.1180.0620.1060.0840.102
Operating Cash Flow Sales Ratio0.0200.0110.0170.0140.017
Free Cash Flow Operating Cash Flow Ratio0.8750.7720.8640.8310.876
Debt Service Coverage Ratio1.3772.7712.6811.134-0.118
Interest Coverage Ratio7.50910.58124.3738.952-4.129
Short Term Operating Cash Flow Coverage Ratio2.8173.3576.8283.1884.578
Operating Cash Flow Coverage Ratio0.5200.2570.6710.5490.538
Capital Expenditure Coverage Ratio7.9724.3827.3625.9138.067
Dividend Paid And Capex Coverage Ratio4.5392.3033.7252.8273.300
Dividend Payout Ratio0.2860.3160.5861.591-0.596
Enterprise Value Multiple17.58414.79712.45017.917284.933

Sparkline shows each ratio oldest → newest (left → right).

How the latest year compares

For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower

MetricCurrentvs 1Y agovs 5Y avg
Gross Profit Margin 3.8% ▲0.2% ▲0.3%
Ebit Margin 1.0% ▼-0.1% ▲0.5%
Ebitda Margin 1.4% ▼-0.0% ▲0.5%
Operating Profit Margin 1.0% ▲0.0% ▲0.5%
Pretax Profit Margin 0.9% ▼-0.1% ▲0.4%
Continuous Operations Profit Margin 0.7% ▼-0.0% ▲0.4%
Net Profit Margin 0.7% ▼-0.0% ▲0.4%
Bottom Line Profit Margin 0.7% ▼-0.0% ▲0.4%
Current Ratio 0.883 ▼-0.052 ▼-0.092
Quick Ratio 0.489 ▼-0.014 ▼-0.039
Solvency Ratio 0.044 ▲0.002 ▲0.017
Cash Ratio 0.111 ▲0.011 ▼-0.015
Price To Earnings Ratio 32.677 ▲6.751 ▲3.457
Price To Earnings Growth Ratio 2.680 ▲2.380 ▲2.149
Forward Price To Earnings Growth Ratio 2.680 ▲2.380 ▲2.149
Price To Earnings Diluted Ratio 32.858 ▲6.811 ▲3.528
Price To Earnings Diluted Growth Ratio 2.717 ▲2.417 ▲2.178
Price To Book Ratio -19.447 ▼-4.888 ▼-5.372
Price To Sales Ratio 0.221 ▲0.039 ▲0.079
Price To Free Cash Flow Ratio 12.390 ▼-9.495 ▲0.906
Price To Operating Cash Flow Ratio 10.836 ▼-6.055 ▲1.347
Debt To Assets Ratio 0.174 ▼-0.002 ▲0.029
Debt To Equity Ratio -3.451 ▼-0.090 ▲0.248
Debt To Capital Ratio 1.408 ▼-0.016 ▼-0.321
Long Term Debt To Capital Ratio 1.724 ▲0.172 ▼-0.699
Financial Leverage Ratio -19.875 ▼-0.773 ▲6.038
Working Capital Turnover Ratio -66.254 ▲69.465 ▲46.773
Operating Cash Flow Ratio 0.118 ▲0.056 ▲0.024
Operating Cash Flow Sales Ratio 0.020 ▲0.010 ▲0.005
Free Cash Flow Operating Cash Flow Ratio 0.875 ▲0.103 ▲0.031
Debt Service Coverage Ratio 1.377 ▼-1.394 ▼-0.192
Interest Coverage Ratio 7.509 ▼-3.073 ▼-1.948
Short Term Operating Cash Flow Coverage Ratio 2.817 ▼-0.541 ▼-1.337
Operating Cash Flow Coverage Ratio 0.520 ▲0.264 ▲0.013
Capital Expenditure Coverage Ratio 7.972 ▲3.590 ▲1.233
Dividend Paid And Capex Coverage Ratio 4.539 ▲2.236 ▲1.200
Dividend Payout Ratio 0.286 ▼-0.030 ▼-0.150
Enterprise Value Multiple 17.584 ▲2.787 ▼-51.953

Key metrics

MetricTrend20262025202420232022
Market cap$56.06B$40.49B$23.95B$24.68B$14.58B
Enterprise value$61.16B$45.96B$24.43B$25.78B$15.67B
EV / Sales0.24x0.21x0.11x0.13x0.09x
EV / Op. cash flow11.82x19.17x6.49x9.07x5.02x
EV / Free cash flow13.52x24.84x7.51x10.91x5.73x
EV / EBITDA17.58x14.80x12.45x17.92x284.93x
Net debt / EBITDA1.46x1.76x0.24x0.76x19.78x
Current ratio0.88x0.94x0.98x1.00x1.08x
Income quality3.04x1.53x4.41x8.59x-3.35x
Graham net-net-$153-$139-$109-$99-$86
Tax burden78.8%74.3%70.9%49.8%119.6%
Interest burden86.2%90.7%95.9%88.8%123.1%
Working capital-$5.15B-$2.52B-$756.0M-$3.0M$2.38B
Invested capital$12.50B$12.51B$8.22B$8.54B$12.38B
Return on assets3.0%2.9%1.9%0.8%-2.1%
Operating ROA4.7%4.6%2.8%1.7%-1.4%
Return on tangible assets3.9%3.8%2.2%0.9%-2.6%
Return on equity-59.5%-56.1%-26.5%-11.2%132.3%
Return on invested capital13.2%11.4%8.8%3.6%-4.3%
Return on capital employed19.5%16.0%13.1%7.8%-4.6%
Earnings yield3.1%3.9%3.6%1.3%-6.4%
Free cash flow yield8.1%4.6%13.6%9.6%18.8%
Capex / Op. cash flow12.5%22.8%13.6%16.9%12.4%
Capex / Depreciation67.9%69.2%72.0%69.5%53.5%
Capex / Sales0.3%0.2%0.2%0.2%0.2%
SG&A / Sales2.4%2.4%2.2%2.3%2.5%
R&D / Sales0.0%0.0%0.0%0.0%0.0%
Stock comp / Sales0.1%0.1%0.1%0.0%0.0%
Intangibles / Total assets23.8%22.9%14.3%14.0%17.4%
Days sales outstanding20d22d19d20d21d
Days payables outstanding57d59d53d55d57d
Operating cycle46d50d44d49d54d
Cash conversion cycle-11d-9d-9d-6d-3d

Change by theme

Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.

Change over 1 year

Valuation
Market cap ▲+38.5%EV / Sales ▲+16.5%EV / EBITDA ▲+18.8%EV / Op. cash flow ▼-7.354Earnings yield ▼-0.008
Profitability
Return on equity ▼-0.033Return on assets ▲+0.001Return on invested capital ▲+0.019Return on capital employed ▲+0.035Operating ROA ▲+0.001Income quality ▲+1.507Tax burden ▲+0.045
Efficiency
Days sales outstanding ▼-1.882Days payables outstanding ▼-1.937Operating cycle ▼-4.710Cash conversion cycle ▼-2.773Capex / Sales +0.000R&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.052Net debt / EBITDA ▼-0.297Working capital ▼-2627000000.000Invested capital ▼-9000000.000Intangibles / Total assets ▲+0.009

Change over 5 years

Valuation
Market cap ▲+284.4%EV / Sales ▲+178.3%EV / EBITDA ▼-93.8%EV / Op. cash flow ▲+6.800Earnings yield ▲+0.095
Profitability
Return on equity ▼-1.918Return on assets ▲+0.051Return on invested capital ▲+0.176Return on capital employed ▲+0.241Operating ROA ▲+0.061Income quality ▲+6.381Tax burden ▼-0.408
Efficiency
Days sales outstanding ▼-1.450Days payables outstanding ▲+0.524Operating cycle ▼-8.267Cash conversion cycle ▼-8.791Capex / Sales +0.000R&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.195Net debt / EBITDA ▼-18.318Working capital ▼-7536000000.000Invested capital ▲+127000000.000Intangibles / Total assets ▲+0.064

Employee count

Peer market caps

Recent news